Economy · Full coverage
Teva Reports Strong Q2 Revenue, Raises Full-Year Forecast for Branded Drugs
How 2 Israeli newsrooms covered this story — translated into English and compared side by side.
Unrated 2
First reported by Globes · 34 minutes ago
What happened
Teva exceeded revenue expectations in Q2 2026 with $4.1 billion, driven by a 43% rise in branded drug sales, and raised its full-year forecast to $3.7 billion. Key drugs Austedo, Ajovy, and Yescarta all showed strong growth, supporting CEO Richard Francis's strategy to focus on branded drugs over generics.
- 01Teva's Q2 revenue reached $4.1 billion, beating analyst expectations.
- 02Branded drug sales grew 43%, surpassing $1 billion for the first time in a quarter.
- 03Austedo revenue rose 40% to $696 million, Ajovy grew 56% to $244 million.
- 04Yescarta, a new schizophrenia drug, increased revenue by 43% to $77 million.
- 05Teva raised its full-year branded drug revenue forecast to $3.7 billion, up 17%.
- 06CEO Richard Francis's strategy focuses on expanding branded drugs over generics.
Summary translated & synthesized from the sources below by baba. Read each original for the full report.
Full coverage · 2 outlets
The same event, reported separately by each newsroom. Open a few to compare what each emphasizes — and what they leave out.
Related stories
Teva Shares Continue Decline Amid Market Volatility and Sector ComparisonsJul 19, 2026Teva Finance Chief Sells Nearly NIS 62 Million in Shares as Stock SurgesJun 16, 2026Novocure Shares Surge Over 20% on Strong Q2 2026 Cancer Treatment Revenue Beat6 days agoHealthcare Stocks Rally on Biotech Gains and New Drug InnovationsJul 21, 2026Teva’s Pursuit of a $2 Billion Exit From TAPI Ends With Another 250 Job CutsJun 10, 2026Teva Reports Positive Phase 1b Results for Vitiligo Antibody, Plans Phase 2b in 2026Jul 7, 2026